Table 1 The patients’ characteristics
Case | Eye affected | Durations (days) | Medical treatment before cyclophotocoagulation | Presenting IOP (mmHg) | VA (LogMAR) |
|---|---|---|---|---|---|
1 | Left | 7 | 1% pilocarpine QID, 2% carteolol Q12H, 0.2% Brimonidine BID | 43.2 | HM |
2 | Left | 11 | 1% pilocarpine Q2H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 250 ml QD | 43.6 | 1.0 |
3 | Right | 7 | 1% pilocarpine QID, 2% carteolol Q12H, 0.2% Brimonidine BID, intravenous 20% mannitol 400 ml QD | 45.0 | 2.0 |
4 | Left | 6 | 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, oral Methazolamide 50 mg BID, intravenous 20% mannitol 400 ml Q12H | 48.6 | 0.9 |
5 | Right | 23 | 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 250 ml Q12H | 54.2 | HM |
6 | Left | 20 | 1% pilocarpine TID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 50 mg BID | 58.7 | HM |
7 | Left | 15 | 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID | 44.8 | FC |
8 | Right | 17 | 1% pilocarpine QID, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 250 ml QD | 47.0 | 1.0 |
9 | Right | 12 | 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 400 ml QD | 50.0 | FC |